top of page

SURMOUNT−2試験

The SURMOUNT-2 trial was a clinical trial that examined the efficacy and safety of tirzepatide (Zepbound) in obese patients with type 2 diabetes. It is known that weight loss is difficult for people with diabetes, but this trial showed that it is possible to achieve both blood sugar control and weight loss.

​Exam Overview

  • Subjects: 938 type 2 diabetes patients with a BMI of 27 or higher and HbA1c of 7-10%

  • Methods: Tirzepatide 10 mg, 15 mg, or placebo was administered by subcutaneous injection once weekly.

Key results

名称未設定のデザイン (1).png
名称未設定のデザイン (1).png
名称未設定のデザイン (1).png
名称未設定のデザイン (1).png
名称未設定のデザイン (1).png
名称未設定のデザイン (1).png

Weight Loss Effect

10mg group: Average −17.8%

15mg group: Average −22.7%

Placebo group: −1.7%

→ Most patients achieved weight loss of approximately 20%.

 

Percentage achieving ≥5% weight loss

10mg group: 94%

15mg group: 96%

Placebo group: 20%

 

Improvement in Metabolic Parameters

HbA1c decreased by an average of 0.67%

Improvement in fasting blood glucose levels

Enhanced insulin sensitivity

 

Improvement in Cardiovascular Risk Factors

Blood pressure (systolic: decreased by approximately 11-12 mmHg)

Triglycerides (reduced by approximately 50%)

Decreased uric acid levels

 

Improved body fat

Visceral fat: Approximately 40% or more reduction

Subcutaneous fat: Approximately 30% or more reduction

Significant improvement in hepatic fat (Fatty liver improvement rate around 70%)

 

Patient Quality of Life (QOL)

Significant improvement in scores related to physical function and quality of life

bottom of page